SCHEMBL13837698

SCHEMBL13837698

CCOC(=O)c1c(-c2ccc(OC)cc2F)csc1N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 10/20 1.00
ALDH1A1 P00352 8/20 0.55
HSD17B10 Q99714 6/20 0.55
HPGD P15428 2/20 0.55
MAPT P10636 6/20 0.54
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
ALOX15 P16050 3/20 0.54
GAA P10253 2/20 0.54
MPI P34949 1/20 0.54
USP2 O75604 1/20 0.54
KEAP1 Q14145 1/20 0.54
MAPK1 P28482 3/20 0.53
LMNA P02545 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
PRKCI P41743 2/20 0.52
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290594 0.87 PRKCZ (0.77) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL689196 0.82 PRKCZ (0.78) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL689530 0.82 PRKCZ (0.69) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL689790 0.80 ALDH1A1 (0.78) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL8289403 0.79 PRKCZ (0.66) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL13837727 0.78 PRKCZ (1.00) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL8290826 0.77 PRKCZ (0.79) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL688430 0.76 PRKCZ (0.63) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL689204 0.75 PRKCZ (1.00) PRKCZALDH1A1HSD17B10HPGDMAPT
SCHEMBL8290591 0.75 PRKCZ (0.71) PRKCZALDH1A1HSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889672-B2 Compounds, formulations, and methods of protein kinase C inhibition THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-18 US disclosed
US-8889672-B2 Compounds, formulations, and methods of protein kinase C inhibition THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-11-18 US disclosed
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition THE PENN STATE RESEARCH FOUNDATION (US) 2012-11-29 US disclosed
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition THE PENN STATE RESEARCH FOUNDATION (US) 2012-11-29 US disclosed
WO-2012149452-A1 COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302561-A1 Compounds, Formulations, and Methods of Protein Kinase C Inhibition PRKCA, PRKCH, PRKCI PRKCZ 5/4885ALDH1A1 4665/4885HSD17B10 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.